BioGaia AB (publ) is a Sweden-based biotechnology company specializing in the development, manufacturing and marketing of probiotic products for human and animal health. The company’s core research centers on select Lactobacillus reuteri strains, supported by extensive clinical studies to promote digestive wellness, immune support and oral health. BioGaia collaborates with academic institutions and healthcare organizations to translate scientific findings into consumer and medical applications.
BioGaia’s product portfolio includes probiotic drops, chewable tablets and oral health lozenges designed for infants, children and adults. The company also supplies clinically oriented nutritional supplements and medical foods under its own brand and through partnerships with pharmaceutical and consumer health companies. In the animal health segment, BioGaia offers tailored probiotic solutions to support gastrointestinal balance in livestock and companion animals.
Products are distributed in more than 90 countries via a network of distributors, pharmacies, hospitals and retail chains. BioGaia maintains regional offices and subsidiaries across Europe, North America and Asia, and has formed strategic alliances with global food, beverage and healthcare groups to incorporate its probiotic strains into infant formulas, dairy products and other consumer items.
Founded in 1990 and headquartered in Stockholm, BioGaia AB (publ) has been listed on Nasdaq Stockholm’s small cap segment since 2004 and trades in the United States on the OTC Markets under the symbol BIOGY. The company’s executive team brings together expertise in microbiology, clinical research and international business to drive ongoing innovation and expand BioGaia’s presence in both consumer and clinical markets worldwide.
AI Generated. May Contain Errors.
Free BIOGY Stock Alerts